Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920946 · ClinicalTrials.gov registry record · Phase 3
A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease
A Phase 3 study of Huntington Disease, sponsored by Medivation.
- Completed
- Registry status
- Phase 3
- Development phase
- 403
- Enrollment target
- 20
- Study locations
NCT00920946: Completed Phase 3 study of Huntington Disease, sponsored by Medivation.
NCT00920946 is a Phase 3 study of Huntington Disease that has completed, run by Medivation. The registered enrollment target is 403 participants, below the 624-participant average among 35 other Huntington Disease trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00920946, a Phase 3 study of Huntington Disease, has completed, sponsored by Medivation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 403 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if Dimebon is safe and effective for the treatment of cognitive impairment in Huntington disease.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Dimebon
Study Locations (20)
California
- - Davis
- - Irvine
- - La Jolla
- - San Francisco
Florida
- - Gainsville
- - Miami
Kansas
- - Kansas City
- - Wichita
New York
- - New York
- - Rochester
North Carolina
- - Durham
- - Winstom-Salem
Ohio
- - Cleveland
- - Columbus
Arizona
- - Scottsdale
Idaho
- - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 403 participants |
| Start Date | 2009-07 |
| Phase | Phase 3 |
What the finished NCT00920946 record still lists
NCT00920946 is an interventional study that assigns participants to a tested intervention. The registered 403 participants enrollment target is mid-sized for trials with a published cap, below the 624-participant average among 35 other Huntington Disease trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00920946 names 20 study sites across 12 states, led by California, Florida, Kansas.
Frequently Asked Questions
What is clinical trial NCT00920946 about?
NCT00920946 is a clinical study titled "A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease". The purpose of this study is to determine if Dimebon is safe and effective for the treatment of cognitive impairment in Huntington disease.
What is the current status of trial NCT00920946?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 403 participants. The study started on 2009-07.
What conditions does trial NCT00920946 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT00920946?
The interventions under investigation include: Placebo (OTHER), Dimebon (DRUG).
Who is sponsoring clinical trial NCT00920946?
This trial is sponsored by Medivation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00920946 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Idaho, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00920946's enrollment target sits among peer trials
403 10th of 35 higher than 26 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
RECRUITING · Phase 3
-
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
COMPLETED · Phase 3
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Longitudinal Endpoint Assessment of Disease Burden in HD
RECRUITING
-
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
RECRUITING
-
Extracellular Vesicles for HD
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05647122 · 403 participants · Phase 1
First in Human Study of AZD9592 in Solid Tumors
- NCT05674799 · 403 participants · NA
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
- NCT06244771 · 403 participants · Phase 1
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- NCT05049057 · 404 participants · Phase 2
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia